BDBM277657 US10072026, Example 8-6::US10947254, Example 8-6

SMILES Cc1cc(Nc2nc(N[C@H]3C[C@@H]4CC[C@H](C3)N4Cc3ccncc3)c3cccnc3c2F)n[nH]1

InChI Key InChIKey=DXNJPSCQUAIWOR-UHFFFAOYSA-N

Data  8 KI

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 8 hits for monomerid = 277657   

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277657(US10072026, Example 8-6 | US10947254, Example 8-6)
Affinity DataKi:  0.550nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277657(US10072026, Example 8-6 | US10947254, Example 8-6)
Affinity DataKi:  0.550nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277657(US10072026, Example 8-6 | US10947254, Example 8-6)
Affinity DataKi:  0.550nMpH: 7.5Assay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277657(US10072026, Example 8-6 | US10947254, Example 8-6)
Affinity DataKi:  0.550nMpH: 7.5Assay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277657(US10072026, Example 8-6 | US10947254, Example 8-6)
Affinity DataKi:  50nMpH: 7.5Assay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2018
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277657(US10072026, Example 8-6 | US10947254, Example 8-6)
Affinity DataKi:  50nMpH: 7.5Assay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2018
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277657(US10072026, Example 8-6 | US10947254, Example 8-6)
Affinity DataKi:  50nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM277657(US10072026, Example 8-6 | US10947254, Example 8-6)
Affinity DataKi:  50nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent